WHO ICTRP trial
AVX754 (nucleoside reverse transcriptase inhibitor) to treat drug resistant HIV
ACTRN12605000742673 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Recruiting
Key facts
| Trial ID | ACTRN12605000742673 |
|---|---|
| Public title | AVX754 (nucleoside reverse transcriptase inhibitor) to treat drug resistant HIV |
| Scientific title | A Phase II, randomised, double-blinded, dose ranging study of AVX754 to reduce the viral load versus lamivudine in treatment experienced HIV-1 infected patients with the M184V mutation in reverse transcriptase. |
| Primary sponsor | Avexa Ltd |
| Secondary sponsors | Avexa Ltd |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | Australia |
| Conditions | HIV Infections; HIV Infections;Infection - Acquired immune deficiency syndrome (AIDS / HIV) |
| Interventions | 600mg or 800mg AVX754 (a new drug treatment of HIV) for 48 weeks. This study is a phase IIb randomised, double-blind, multi-centre, dose-ranging, controlled parallel group study where lamivudine is the comparator. The study will enrol… |
| Registration date | Nov 15, 2005 |
| Target size | 60 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: